Meningococcal B Vaccine Does Not Prevent Gonorrhea, RCT Finds

A large-scale randomized control trial (RCT) has found that the meningococcal B vaccine (4CMenB) does not prevent the acquisition of gonorrhea. This finding contradicts previous evidence from observational studies.

Study Details Unveiled

The results were presented by Professor Kate Seib from Griffith University at the Conference on Retroviruses and Opportunistic Infections in Denver, Colorado. The study, a collaborative effort by Griffith University's Institute for Biomedicine and Glycomics and the Kirby Institute at UNSW Sydney, focused on gay and bisexual men. This population was specifically chosen due to its particularly high risk of gonorrhea, which remains a significant public health concern, especially with the rise of antibiotic-resistant strains.

The double-blind, randomized, placebo-controlled trial involved 587 gay and bisexual men. Participants received either the meningococcal vaccine or a saline placebo.

Professor Kate Seib stated that gonorrhea incidence was approximately 48% per year across both groups, indicating no preventive effect from the vaccine.

These results also align with findings from the smaller DOXYVAC open-label trial.

Implications for Prevention Strategies

Professor Andrew Grulich from the Kirby Institute noted that an effective gonorrhea vaccine would profoundly change existing prevention strategies.

While the 4CMenB vaccine is approved in Australia since 2013 and remains safe and effective for preventing meningococcal disease, it does not offer protection against gonorrhea.

Individuals who received the 4CMenB vaccine with the expectation of gonorrhea prevention are advised to consider other prevention methods. Professor Grulich strongly recommends continued use of condoms and regular testing.

Study Population and Generalizability

The RCT, named 'GoGoVax', specifically included gay and bisexual men with a recent history of gonorrhea or syphilis. This selection aimed to ensure a higher likelihood of participants acquiring gonorrhea during the study period.

Researchers acknowledge that the high rates of prior gonorrhea in this specific study population might affect the generalizability of the findings to other populations. However, the results are considered an important finding for high-risk gay and bisexual men.

Understanding RCTs vs. Observational Studies

GoGoVax was initiated following several observational studies that had previously suggested an association between the meningococcal B vaccine and reduced gonorrhea incidence. Based on these earlier data, some countries currently offer the vaccine to gay and bisexual men at high risk for gonorrhea.

Observational studies, by their nature, can be influenced by confounding factors. For example, some case-control studies compared 4CMenB vaccination rates in people with gonorrhea to those with chlamydia, noting lower 4CMenB vaccination rates in gonorrhea cases. Yet, other unmeasured factors could potentially explain these observed differences.

RCTs are regarded as the gold standard in medical research because proper randomization removes potential confounding factors.

Professor Grulich confirmed that good-quality randomization was achieved in the GoGoVax trial. This process successfully balanced confounding factors between the vaccine and placebo groups, thereby providing robust evidence regarding the lack of a cause-and-effect relationship for gonorrhea prevention from the 4CMenB vaccine.